New reverse transcriptase inhibitors

Advances in Experimental Medicine and Biology

Volumn 458, Issue , 1999, Pages 183-197

  Crowe, S ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

9 [2 [BIS [(ISOPROPOXYCARBONYL)OXY]METHOXY]PHOSPHINOYL]ADENINE FUMARATE; ABACAVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; CLARITHROMYCIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PRODRUG; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CROSS RESISTANCE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; INSOMNIA; LIVER TOXICITY; MUTATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PLACENTAL TRANSFER; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VERTIGO; VIRUS LOAD; VOMITING;

HUMAN IMMUNODEFICIENCY VIRUS; OXY;

EID: 0033281841     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4743-3_18     Document Type: Conference Paper

References (63)

1. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
2. A novel human phosphotransferase highly specific for adenosine
3. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity
4. Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism
5. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
6. 1592U89 A novel carbocyclic nucleoside analog with potent anti-HIV activity, is synergistic in combination with 141 W94, on HIV protease inhibitor
7. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
8. Antiretroviral activity and resistance profile of the carbocyclic nucleoside HIV reverse transcriptase inhibitor 1592U89
9. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
10. 1592U89 - A second generation nucleoside analogue
11. Evaluation of potential pharmacokinetic (PK) drug interaction between 141W94 and 1592U89 in HIV+ patients
12. Preliminary data from a phase I/II study on the safety and antiviral efficacy of the combination of 141W94 plus 1592U89 in HIV-infected patients with 150 to 400 CD4+ cells/mm
13. 3
14. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266
15. L-743-726 (DMP-266); a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
16. Impact of mutation, plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 non nucleoside reverse transcriptase inhibitor, DMP 266
17. Mutations associated with viral load rebound in patients treated with the HIV-1 non nucleoside reverse transcriptase inhibitor DMP 266 in combination with the HIV-1 protease inhibitor crixivan®
18. Long-term anti-HIV-1 activity and tolerability of DMP 266 in combination with indinavir
19. Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate (NFV) in healthy volunteers
20. Plasma of fluconazole (FL) are not altered by coadministration of DMP 266 in healthy volunteers
21. DMP 266 cerebrospinal fluid concentrations (CSF) after oral administration
22. Long term (50 weeks) anti-HIV-1 activity and tolerability (24 weeks) of DMP 266 in combination with indinavir (IDV) (DMP 266-003, cohort III)
23. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro
24. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 combined with (-)2′,3′-dideoxy-3′-thiacytidine
25. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds
26. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long term culture of HIV-1-infected cells
27. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: Potential approach towards effective chemotherapy against HIV-1
28. Pharmacokinetics (PK) and safety of single escalating doses of MKC-442 in HIV-infected volunteers
29. Preliminary efficacy and safety of MKC-442 in HIV infected patients
30. Clinical experience with non nucleoside reverse transcriptase inhibitors L-697,661 and nevirapine
31. Antiviral drugs. The use of antibiotics, a clinical review of antibacterial, antifungal and antiviral drugs
32. U-09152 a potent inhibitor of human immunodeficiency virus type 1 replication
33. Bishetaroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azudi-3′-deoxythymidine or 2′,3′-dideoxytytidine synergistically inhibits HIV-1 replication in vitro
34. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon
35. A mutation in reverse transcriptase of bis(heteraryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
36. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
37. Combination therapy with delavirdine mesylate (Delavirdine) and AZT; virology data from an Europe phase II trial
38. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine
39. Steady state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test
40. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate
41. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor
42. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells
43. Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes
44. Identification of a mutation of codon 65 in the IKKC motif of reverse transcriptase that encodes HIV resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine
45. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the HIV-1 reverse transcriptase
46. The K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross resistance to 9-(2-phosphonylmethoxyethyl)adenine
47. Early treatment with 9-(2-phosphonylmethoxyethyl)adenine reduced virus burdens for a prolonged period in SIV-infected rhesus macaques
48. In vitro selection and molecular characterisation of human immunodeficiency virus type 1 with reduced sensitivity to 9-(2-phosphonylmethoxyethyl)adenine
49. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis
50. A novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) in vitro
51. Genotypic characterisation of HIV-1 variants isolated from AIDS patients after prolonged therapy with adefovir dipivoxil (bis-POM-PMEA)
52. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats
53. Pharmacokinetic profile of 9-[2-(bis-pivaloyloxymethyl) phosphonylmethoxyethyl]adenine (bis-POM PMEA), an orally bioavailable prodrug of the antiviral nucleotide, PMEA
54. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1 infected patients
55. Anti-human immunodeficiency virus (HIV) activity, safety and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients
56. The safety and efficacy of adefovir dipivoxil a novel anti-HIV therapy, in HIV infected adults
57. Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl) guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice
58. Bis(POC)PMPA an orally bioavailable prodrug of the antiretroviral agent PMPA
59. Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethy)adenine in primary macrophages is determined by drug metabolism, nucleotide pools and cytokines
60. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine
61. In vitro selection and characterisation of HIV-1 variants with reduced susceptibility to PMPA
62. PMPA safety, pharmacokinetics and antiretroviral activity when administered as a single dose and for seven consecutive days to patients with HIV-infection